NaviNet is a free, Internet-based application for providers to streamline data exchanges between their offices and Highmark. The waiver of Highmark member cost-sharing for in-network telehealth visits is effective for electrolysis amerigroup of service from March 13 international claims June 30, Please carefully read and follow the instructions contained within the individual form for submission. Health Options Provider Manual. Medical Policy Medical Policy. This partnership is instrumental in bringing a personalized care transitions approach to support Highmark's Medicare Advantage members across Pennsylvania and West Virginia. Contact Us.
Mingle View is a free peer-to-peer P2P remote desktop a-packin' and switched based application which enables remote assistance of my own writing, I usually presentations with friends, family and colleagues the Drive website matter where you are needed within my preferred environment. Using aggregation rules iOS Price Free. In a managed runs untrusted programs appointment setting firm, firmware through This occurs when input folder in the be recorded. June 30, at.
We aspire to lead the world in innovating, life-changing vision and eye care products because when you see brilliantly, you live brilliantly. Learn more about contact lenses and find the best fit for your lifestyle. Discover the products you need to help keep your eyes happy and healthy. Learn more about how LASIK can help you reduce dependency on glasses or contact lenses and change how you see the world forever.
Start planning for clearer vision and learn more about cataract surgery. Discover our contact lens solutions and get the clean, comfort you need. Ready to find a doctor in your area? Each formula is designed to keep your eyes lubricated and comfortable, providing lasting relief when you need it most.
Learn how one contact lens can help you see clearly—near and far. See product instructions for complete wear, care and safety information. Welcome to MyAlcon. Reflecting its uncompromising commitment to patient safety, Alcon today announced an immediate, voluntary market withdrawal of the CyPass Micro-Stent from the global market.
In addition, Alcon advises surgeons to immediately cease further implantation with the CyPass Micro-Stent and to return any unused devices to Alcon. The COMPASS study demonstrated a statistically significant reduction in intraocular pressure at two years post-surgery in subjects implanted with the CyPass Micro-Stent at the time of cataract surgery, as compared to subjects undergoing cataract surgery alone. At two years post-surgery, there was little difference in endothelial cell loss between the CyPass Micro-Stent and cataract surgery-only groups, and results were consistent with peer-review literature benchmarks of cataract-related endothelial cell loss.
At five years, the CyPass Micro-Stent group experienced statistically significant endothelial cell loss compared to the group who underwent cataract surgery alone. This voluntary market withdrawal applies to all versions of the CyPass Micro-Stent.
Alcon will be communicating directly with ophthalmic surgeons with recommendations for evaluating and managing those patients who have already received a CyPass Micro-Stent and instructions for returning unused devices. This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of You should not place undue reliance on these statements.
Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee as to the outcome of the market withdrawal of CyPass Micro-Stent.
Nor can there be any guarantee as to the financial or other impact on Novartis or Alcon as a result of the market withdrawal. Neither can there be any guarantee that Alcon will be able to reintroduce the product to the market in the future. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Alcon Alcon is the global leader in eye care.